Skip to content

VITROS 1072693Recalls & reported problems

Ortho Clinical Diagnostics · VITROS Immunodiagnostic Products Signal Reagent · Class 1

Adverse event reports
2
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 10758750008360), received between Dec 19, 2025 and Jan 8, 2026 — classified as 2 malfunctions.

The most frequently reported specific device problem is “Low Test Results” (2 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 1 reportsJan 2026: 1 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Low Test Results2

Patient problems

  • No Clinical Signs, Symptoms or Conditions2

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJan 8, 2026Low Test Results

    A CUSTOMER CONTACTED THE ORTHO CLINICAL DIAGNOSTICS (ORTHO) TECHNICAL SOLUTION CENTER (TSC) TO REPORT A LOWER-THAN-EXPECTED NT-PROBNP II (NTBNP II) RESULT WAS OBTAINED WHEN PROCESSING A NON-VITROS BIORAD LIQUICHEK CARDIAC MARKERS PLUS CONTROL LT QUALITY CONTROL (QC) FLUID LOT 1003102 ON A VITROS 5600 INTEGRATED SYSTEM. BIORAD QC LOT 1003102 QC FLUID RESULT OF 51.0 PG/ML VERSUS THE EXPECTED RESULT OF 153.2 PG/ML BIASED RESULTS OF THE MAGNITUDE AND DIRECTION OBSERVED MAY LEAD TO INAPPROPRIATE PHYSICIAN ACTION IF THEY WERE TO OCCUR UNDETECTED ON PATIENT SAMPLES. THE LOWER-THAN-EXPECTED VITROS NTBNP II RESULT WAS OBTAINED WHEN PROCESSING NON-PATIENT FLUID. THE CUSTOMER MADE NO INDICATION THAT ANY PATIENT SAMPLE RESULTS HAD BEEN AFFECTED. THERE WERE NO REPORTED ALLEGATIONS OF HARM AS A RESULT OF THIS EVENT. THIS REPORT CORRESPONDS TO ORTHO CLINICAL DIAGNOSTICS INC (ORTHO) COMPLAINT NUMBER (B)(4) AND REPORTABILITY ASSESSMENT (B)(4).

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24009234 ↗
  • MalfunctionDec 19, 2025Low Test Results; Low Test Results

    THE INVESTIGATION HAS DETERMINED THAT A LOWER-THAN-EXPECTED NT PROBNP II (NTBNP II) RESULT WAS OBTAINED WHEN PROCESSING A NON-VITROS QUALAB BIOTECH QUALITY CONTROL (QC) FLUID LOT 2510A05423 ON A VITROS 5600 INTEGRATED SYSTEM. BIOTECH LOT 2510A05423 = 159.0 PG/ML VERSUS THE EXPECTED RESULT OF 352.67 PG/ML BIASED RESULTS OF THE MAGNITUDE AND DIRECTION OBSERVED MAY LEAD TO INAPPROPRIATE PHYSICIAN ACTION IF THEY WERE TO OCCUR UNDETECTED. THE LOWER-THAN-EXPECTED VITROS NTBNP II RESULT WAS OBTAINED FROM A NON-PATIENT QUALITY CONTROL FLUID. HOWEVER, THE INVESTIGATION CANNOT CONCLUDE THAT PATIENT SAMPLE RESULTS WOULD NOT BE AFFECTED IF THE EVENT WERE TO RECUR UNDETECTED. THERE WERE NO ALLEGATIONS OF PATIENT HARM AS A RESULT OF THE EVENT. THIS REPORT CORRESPONDS TO ORTHO CLINICAL DIAGNOSTICS INC (ORTHO) COMPLAINT NUMBER (B)(4) AND REPORTABILITY ASSESSMENT (B)(4).

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 23848556 ↗

Other General purpose reagent devices

All General purpose reagent devices →

Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.